<DOC>
	<DOCNO>NCT00942591</DOCNO>
	<brief_summary>Title : Efficacy , safety tolerability Atorvastatin 40 mg patient relapsing-remitting multiple sclerosis treat interferon-beta-1b SWiss Atorvastatin Interferon-Beta 1b Trial In Multiple Sclerosis Short title : `` SWABIMS '' Study phase : Phase IIb study Study design : Multi-center , randomize , rater-blinded , parallel-group-study Switzerland Investigational product : Atorvastatin 40mg every day ( oral ) plus Interferon-beta Reference product : Interferon-beta-1b 250mg give Indication : Relapsing-remitting multiple sclerosis ( RR-MS ) Study objective : Comparison efficacy , safety tolerability combination Atorvastatin 40mg ( per o ) daily Interferon-beta-1b e.o.d patient relapsing-remitting multiple sclerosis compare monotherapy Interferon-beta-1b e.o.d . Primary Endpoint : Proportion patient new T2 lesion 15 month treatment .</brief_summary>
	<brief_title>Atorvastatin 40 mg Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b</brief_title>
	<detailed_description>Background Multiple sclerosis consider chronic inflammatory demyelinate autoimmune disease central nervous system . Statins lipid-lowering drug inhibit 3-hydroxy-3-methylglutaryl-coenzyme A ( HMG-CoA- ) reductase , main regulatory enzyme cholesterol biosynthesis . In recent year many study demonstrate , statins anti-inflammatory immunomodulatory property addition lipid-lowering effect . Therefore , statins seem therapeutic potential immune-mediated disorder multiple sclerosis . Studies experimental allergic encephalomyelitis ( EAE ) , animal model human demyelinate disease multiple sclerosis , well small study patient relapsing-remitting multiple sclerosis show beneficial effect course disease . But also report negative impact statins multiple sclerosis . Therefore , big study need investigate therapeutical potential statin multiple sclerosis . Objective The objective study assess efficacy , safety tolerability combination Atorvastatin 40mg p.o . daily Interferon-beta-1b sc e.o.d compare monotherapy Interferon-beta-1b sc e.o.d patient relapsing-remitting multiple sclerosis . Methods Multi-center , rater-blinded , parallel-group , two arm , randomize study . Patients relapsing-remitting form MS , respect inclusion/exclusion criterion , randomize two equal-size parallel arm three month treatment Interferon-beta-1b , receive Atorvastatin 40mg/d . Enrolment 80 patient ( 1/2 Atorvastatin group ) plan . Patients provide write informed consent treat 15 month . Inclusion criterion : Patients relapsing-remitting form multiple sclerosis disease duration &gt; 3 month &lt; 5 year , least 1 relapse past two year , &gt; 3 Lesions spinal brain-MRI , EDSS score 0 3.5 , inclusive , age 18 55 year . Exclusion criterion : Any disease multiple sclerosis would better explain patient 's sign symptom , Primary progressive MS , Secondary progressive MS , others .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients relapsingremitting form multiple sclerosis ( accord McDonald 's criterion ) At least 1 relapse past two year &gt; 3 Lesions spinal brainMRI EDSS score 0 3.5 , inclusive Age 18 55 year Written inform consent Negative pregnancy test result ( woman ) Exclusion Criteria Any disease multiple sclerosis would better explain patient 's sign symptom Primary progressive MS Secondary progressive MS Uncontrolled severe medical disorder A history drug abuse 6 month prior screen Previous therapy Monoclonal antibody , mitoxantrone , cytotoxic immunosuppressive therapy ( except steroid ) Participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>interferon beta</keyword>
	<keyword>atorvastatin</keyword>
</DOC>